Phellinsin A from Phellinus sp. PL3 exhibits antioxidant activities

Area of Science:

• Natural Product Chemistry
• Biochemistry
• Pharmacology

Background:

• Oxidative stress plays a critical role in cardiovascular diseases, particularly through low-density lipoprotein (LDL) oxidation.
• Natural compounds are a promising source for developing novel antioxidants and therapeutic agents.

Purpose of the Study:

• To investigate the antioxidant and enzyme inhibitory activities of Phellinsin A, a compound isolated from Phellinus sp. PL3.
• To evaluate Phellinsin A's efficacy in preventing LDL oxidation and scavenging free radicals.
• To assess Phellinsin A's inhibitory effect on xanthine oxidase.

Main Methods:

• Isolation of Phellinsin A from Phellinus sp. PL3 culture broth.
• Assessment of LDL antioxidant activity using thiobarbituric acid-reactive substances (TBARS) assay with Cu2+ and AAPH-mediated oxidation.
• Evaluation of macrophage-mediated LDL oxidation and LDL oxidation lag time.
• Determination of 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activity.
• Measurement of xanthine oxidase inhibitory activity.

Main Results:

• Phellinsin A exhibited significant inhibition of Cu2+-mediated LDL oxidation (IC50: 5.3 microM) and AAPH-mediated LDL oxidation (IC50: 2.8 microM).
• The compound demonstrated strong inhibition of macrophage-mediated LDL oxidation (73% at 5 microM) and prolonged the LDL oxidation lag time (192 min at 2 microM).
• Phellinsin A showed superior DPPH free radical scavenging activity (IC50: 1.7 microM) compared to trolox and inhibited xanthine oxidase (IC50: 31.0 microM) more effectively than allopurinol.

Conclusions:

• Phellinsin A possesses significant LDL-antioxidant properties and potent free radical scavenging capabilities.
• The compound's ability to inhibit xanthine oxidase suggests potential applications in managing conditions related to uric acid.
• Phellinsin A represents a promising natural compound with potential therapeutic benefits for oxidative stress-related diseases.